2010/05 - NZZ am Sonntag: "Wir sind auf Krebs-Fonds spezialisiert"
2010/04 - Nextech Venture Holds $33M Close On Fund III, Names New Partner
2009/12 - Marc Faber Report: Sweet Spot Oncology
2009/11 - Sunesis' Voreloxin granted Orphan drug designation by FDA
2009/05 - Nextech Venture invests in Palyon Medical
2009/04 - Nextech Venture invests in Sunesis PIPE
2009/03 - ImVisioN reports successful clinical phase I data
2008/08 - Nextech Venture exited Ganymed Pharmaceuticals successfully
2008/08 - DowJones: Nextech Closes $61M Partnership, Sees Exit
2007/11 - Astellas acquires Agensys for USD 537 million
2007/10 - Ganymed increases financing round
2007/08 - Nextech Venture launches the first "Global Oncology Venture Event"
2007/08 - ImVisioN - Immunotherapeutics for treating allergies
2007/07 - Nextech Venture invests in Agensys
2007/05 - Dow Jones: Nextech Raises $34M For Oncology Drug Fund
2007/04 - Ganymed raises Euro 33.7M in Series C financing round
2007/04 - Ganymed: Spezielle Finanzierungsrunde mit Schweizer Unterstützung
2006/10 - Dr. Myoung-Ok Kwon joins Nextech Venture
2006/10 - Mainzer Krebsforscher Ugur Sahin erhält Go-Bio-Preis
2006/09 - The Genetics Company Inc. enters distributorship agreement with EUROMEDEX
2006/08 - The Genetics Company Inc. renews Long Term Supply Agreement with JSW-Research Ltd.
2006/05 - ImVisioN GmbH obtains exclusive license from MannKind
2006/04 - Ganymed lead antibodies show excellent efficacy and safety in mouse tumor models
2005/07 - Ganymed raises EUR 14.4 million in Series B Financing Round
2005/05 - ImVisioN GmbH appoints Martin Steiner as CEO and acquires broad IP portfolio
2005/02 - Nextech Venture leads The Genetics Company financing
2004/12 - BioVisioN spins off new enterprise with peptide vaccine portfolio
2004/04 - Successful Exit: WebWasher sold to CyberGuard
2003/09 - Spotlight: Interview with Alfred Scheidegger
2001/07 - A little-known star in the world of venture capital
1999/07 - Neue Venture Capital Gesellschaft für Hochtechnologie wird operativ tätig